Southern College of Optometry
16
5
5
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
6.3%
1 terminated/withdrawn out of 16 trials
87.5%
+1.0% vs industry average
38%
6 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Comparison of Two Contact Lens Designs
Role: lead
Effects of Acute Sugar Intake on Choroidal Thickness
Role: lead
Switching From Xiidra to TRYPTYR
Role: lead
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
Role: lead
Switching From Restasis to TRYPTYR
Role: lead
Total30 For Contact Lens Dropouts
Role: lead
Acuvue Oaysis Contact Lens Wearers Being Refit Into P7 Contact Lenses
Role: lead
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
Role: lead
How Does DT1 Sphere Perform in Current and Successful Acuvue MAX Wearers?
Role: lead
Trial of Vision Therapy for Intermittent Exotropia
Role: collaborator
Treating Lid Wiper Epitheliopathy
Role: lead
T30 for Astigmatism in Digital Device Users
Role: lead
Total30 for Astigmatism Contact Lenses
Role: lead
Higher Order Aberration and Relationship With Soft Contact Lens Modulus
Role: lead
Delaying the Onset of Nearsightedness Until Treatment Study
Role: collaborator
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
Role: collaborator
All 16 trials loaded